NURS 6521 Advanced pharmacology Final
Exam- (6 Versions, 600QA), Walden, Latest
2021
1. (MCQ) A 72-year-old patient with chronic kidney disease (CKD) Stage 4 is prescribed a drug
that undergoes primarily renal elimination. The nurse practitioner should anticipate which
pharmacokinetic alteration?
A. Decreased half-life
B. Increased drug clearance
C. Increased half-life
D. Decreased volume of distribution
Rationale: Renal impairment reduces glomerular filtration and tubular secretion, decreasing
drug clearance. When clearance decreases, the elimination half-life increases, leading to drug
accumulation and increased risk of toxicity. This is a fundamental pharmacokinetic principle
requiring dose adjustment in CKD .
2. (MCQ) A patient receives a drug orally, but the prescriber notes that the oral dose must be
significantly higher than the IV dose to achieve the same therapeutic effect. This difference is
primarily explained by:
A. Higher protein binding of the oral formulation
B. First-pass hepatic metabolism
C. Increased renal tubular reabsorption
D. Greater volume of distribution with oral administration
Rationale: First-pass effect refers to the metabolism of a drug in the liver and gut wall
before it reaches systemic circulation. Drugs with high first-pass metabolism have low oral
bioavailability, requiring higher oral doses to achieve therapeutic plasma concentrations .
3. (SATA) Which factors can increase a drug's bioavailability? (Select all that apply.)
A. Administration with food that enhances absorption
B. Intravenous administration
C. Inhibition of hepatic CYP450 enzymes
D. First-pass metabolism
E. Concomitant administration of P-glycoprotein inhibitors
, Rationale: Bioavailability is the fraction of administered drug that reaches systemic
circulation unchanged. IV administration is 100% bioavailable. Food can enhance absorption of
some drugs (e.g., itraconazole). CYP450 inhibitors reduce first-pass metabolism, increasing
bioavailability. P-glycoprotein inhibitors reduce efflux back into the gut lumen. First-pass
metabolism decreases bioavailability .
4. (MCQ) A drug with a narrow therapeutic index (NTI) has which characteristic?
A. Wide margin between therapeutic and toxic doses
B. Small difference between effective and toxic plasma concentrations
C. Predictable dose-response relationship with minimal monitoring
D. Low risk of drug-drug interactions
Rationale: NTI drugs (e.g., warfarin, digoxin, phenytoin, lithium) have small differences
between therapeutic and toxic concentrations. They require therapeutic drug monitoring,
careful dose titration, and vigilance for interactions that could precipitate toxicity .
5. (MCQ) A nurse practitioner is reviewing the mechanism of action of a new drug. The drug
binds to a receptor and produces a submaximal response even at full receptor occupancy. This
drug is best described as a:
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
Rationale: A partial agonist binds to the receptor and produces a response, but the maximal
response is less than that of a full agonist, even at 100% receptor occupancy. Partial agonists
can act as antagonists in the presence of a full agonist (e.g., buprenorphine at mu receptors) .
6. (MCQ) Which statement accurately describes the pharmacodynamic phase of drug action?
A. It studies the amount of drug excreted into breast milk
B. It involves the drug-receptor interaction and the resulting biological effect
C. It is concerned with drug absorption and metabolism
D. It determines the drug's bioavailability
Rationale: Pharmacodynamics refers to what the drug does to the body — receptor binding,
signal transduction, and the resulting physiological effect. Pharmacokinetics, in contrast,
describes what the body does to the drug (absorption, distribution, metabolism, excretion) .
,7. (MCQ) A 68-year-old patient has a serum creatinine of 2.1 mg/dL. The nurse practitioner
should recognize that this patient's:
A. Drug dosing may need adjustment due to reduced renal clearance
B. Renal function is normal for age
C. Hepatic metabolism is likely impaired
D. Volume of distribution is increased
Rationale: An elevated serum creatinine indicates reduced glomerular filtration rate (GFR).
Many drugs require dose adjustment in renal impairment. Creatinine clearance should be
calculated (e.g., Cockcroft-Gault) to guide dosing decisions for renally eliminated drugs.
8. (MCQ) Which of the following statements about competitive antagonists is correct?
A. They irreversibly bind to the receptor
B. They can be overcome by increasing the concentration of the agonist
C. They produce a supramaximal response
D. They bind to an allosteric site on the receptor
Rationale: Competitive antagonists reversibly bind to the same site as the agonist.
Increasing the agonist concentration can displace the antagonist and restore the maximal
response, shifting the dose-response curve to the right without reducing Emax .
9. (SATA) Which of the following are Phase II metabolic reactions? (Select all that apply.)
A. Glucuronidation
B. Sulfation
C. Acetylation
D. Oxidation
E. Reduction
Rationale: Phase II reactions are conjugation reactions that increase water solubility for
excretion. Glucuronidation, sulfation, acetylation, methylation, and glutathione conjugation are
Phase II. Oxidation and reduction are Phase I reactions mediated primarily by CYP450 enzymes .
10. (MCQ) A patient is taking a drug that is a weak acid. To enhance its renal excretion, the
nurse practitioner would recommend:
A. Acidification of the urine
B. Alkalinization of the urine
C. Increasing plasma protein binding
D. Decreasing urinary flow rate
, Rationale: Weak acids are more ionized in alkaline urine. Ionized drugs are not reabsorbed
in the renal tubules and are excreted more readily. Alkalinizing urine with sodium bicarbonate
enhances elimination of weak acids (e.g., salicylates, phenobarbital) .
11. (MCQ) The cytochrome P450 enzyme system is primarily responsible for:
A. Phase I metabolism of drugs
B. Phase II conjugation reactions
C. Renal excretion of drugs
D. Drug absorption in the intestine
Rationale: CYP450 enzymes catalyze Phase I oxidative, reductive, and hydrolytic reactions
that modify drug structure. The most clinically significant is CYP3A4, which metabolizes
approximately 50% of all drugs .
12. (MCQ) A patient is taking warfarin, a drug with a narrow therapeutic index. Which
laboratory parameter should be monitored to assess therapeutic effect?
A. aPTT
B. INR (International Normalized Ratio)
C. Platelet count
D. Bleeding time
Rationale: Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X). The INR is
the standard monitoring parameter for warfarin therapy, with typical target ranges of 2.0–3.0
for most indications and 2.5–3.5 for mechanical mitral valves .
13. (MCQ) Which statement best describes the concept of volume of distribution (Vd)?
A. The rate at which a drug is eliminated from the body
B. The theoretical volume into which the total drug dose would need to be distributed to
achieve the observed plasma concentration
C. The amount of drug bound to plasma proteins
D. The fraction of drug that reaches systemic circulation
Rationale: Vd = Dose / Plasma concentration. A high Vd indicates extensive tissue
distribution (e.g., digoxin, amiodarone); a low Vd indicates confinement to plasma (e.g.,
warfarin, heparin). Vd influences loading dose calculations .
14. (MCQ) A 55-year-old patient with cirrhosis has decreased albumin levels. The nurse
practitioner should monitor for which potential drug-related complication?
Exam- (6 Versions, 600QA), Walden, Latest
2021
1. (MCQ) A 72-year-old patient with chronic kidney disease (CKD) Stage 4 is prescribed a drug
that undergoes primarily renal elimination. The nurse practitioner should anticipate which
pharmacokinetic alteration?
A. Decreased half-life
B. Increased drug clearance
C. Increased half-life
D. Decreased volume of distribution
Rationale: Renal impairment reduces glomerular filtration and tubular secretion, decreasing
drug clearance. When clearance decreases, the elimination half-life increases, leading to drug
accumulation and increased risk of toxicity. This is a fundamental pharmacokinetic principle
requiring dose adjustment in CKD .
2. (MCQ) A patient receives a drug orally, but the prescriber notes that the oral dose must be
significantly higher than the IV dose to achieve the same therapeutic effect. This difference is
primarily explained by:
A. Higher protein binding of the oral formulation
B. First-pass hepatic metabolism
C. Increased renal tubular reabsorption
D. Greater volume of distribution with oral administration
Rationale: First-pass effect refers to the metabolism of a drug in the liver and gut wall
before it reaches systemic circulation. Drugs with high first-pass metabolism have low oral
bioavailability, requiring higher oral doses to achieve therapeutic plasma concentrations .
3. (SATA) Which factors can increase a drug's bioavailability? (Select all that apply.)
A. Administration with food that enhances absorption
B. Intravenous administration
C. Inhibition of hepatic CYP450 enzymes
D. First-pass metabolism
E. Concomitant administration of P-glycoprotein inhibitors
, Rationale: Bioavailability is the fraction of administered drug that reaches systemic
circulation unchanged. IV administration is 100% bioavailable. Food can enhance absorption of
some drugs (e.g., itraconazole). CYP450 inhibitors reduce first-pass metabolism, increasing
bioavailability. P-glycoprotein inhibitors reduce efflux back into the gut lumen. First-pass
metabolism decreases bioavailability .
4. (MCQ) A drug with a narrow therapeutic index (NTI) has which characteristic?
A. Wide margin between therapeutic and toxic doses
B. Small difference between effective and toxic plasma concentrations
C. Predictable dose-response relationship with minimal monitoring
D. Low risk of drug-drug interactions
Rationale: NTI drugs (e.g., warfarin, digoxin, phenytoin, lithium) have small differences
between therapeutic and toxic concentrations. They require therapeutic drug monitoring,
careful dose titration, and vigilance for interactions that could precipitate toxicity .
5. (MCQ) A nurse practitioner is reviewing the mechanism of action of a new drug. The drug
binds to a receptor and produces a submaximal response even at full receptor occupancy. This
drug is best described as a:
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
Rationale: A partial agonist binds to the receptor and produces a response, but the maximal
response is less than that of a full agonist, even at 100% receptor occupancy. Partial agonists
can act as antagonists in the presence of a full agonist (e.g., buprenorphine at mu receptors) .
6. (MCQ) Which statement accurately describes the pharmacodynamic phase of drug action?
A. It studies the amount of drug excreted into breast milk
B. It involves the drug-receptor interaction and the resulting biological effect
C. It is concerned with drug absorption and metabolism
D. It determines the drug's bioavailability
Rationale: Pharmacodynamics refers to what the drug does to the body — receptor binding,
signal transduction, and the resulting physiological effect. Pharmacokinetics, in contrast,
describes what the body does to the drug (absorption, distribution, metabolism, excretion) .
,7. (MCQ) A 68-year-old patient has a serum creatinine of 2.1 mg/dL. The nurse practitioner
should recognize that this patient's:
A. Drug dosing may need adjustment due to reduced renal clearance
B. Renal function is normal for age
C. Hepatic metabolism is likely impaired
D. Volume of distribution is increased
Rationale: An elevated serum creatinine indicates reduced glomerular filtration rate (GFR).
Many drugs require dose adjustment in renal impairment. Creatinine clearance should be
calculated (e.g., Cockcroft-Gault) to guide dosing decisions for renally eliminated drugs.
8. (MCQ) Which of the following statements about competitive antagonists is correct?
A. They irreversibly bind to the receptor
B. They can be overcome by increasing the concentration of the agonist
C. They produce a supramaximal response
D. They bind to an allosteric site on the receptor
Rationale: Competitive antagonists reversibly bind to the same site as the agonist.
Increasing the agonist concentration can displace the antagonist and restore the maximal
response, shifting the dose-response curve to the right without reducing Emax .
9. (SATA) Which of the following are Phase II metabolic reactions? (Select all that apply.)
A. Glucuronidation
B. Sulfation
C. Acetylation
D. Oxidation
E. Reduction
Rationale: Phase II reactions are conjugation reactions that increase water solubility for
excretion. Glucuronidation, sulfation, acetylation, methylation, and glutathione conjugation are
Phase II. Oxidation and reduction are Phase I reactions mediated primarily by CYP450 enzymes .
10. (MCQ) A patient is taking a drug that is a weak acid. To enhance its renal excretion, the
nurse practitioner would recommend:
A. Acidification of the urine
B. Alkalinization of the urine
C. Increasing plasma protein binding
D. Decreasing urinary flow rate
, Rationale: Weak acids are more ionized in alkaline urine. Ionized drugs are not reabsorbed
in the renal tubules and are excreted more readily. Alkalinizing urine with sodium bicarbonate
enhances elimination of weak acids (e.g., salicylates, phenobarbital) .
11. (MCQ) The cytochrome P450 enzyme system is primarily responsible for:
A. Phase I metabolism of drugs
B. Phase II conjugation reactions
C. Renal excretion of drugs
D. Drug absorption in the intestine
Rationale: CYP450 enzymes catalyze Phase I oxidative, reductive, and hydrolytic reactions
that modify drug structure. The most clinically significant is CYP3A4, which metabolizes
approximately 50% of all drugs .
12. (MCQ) A patient is taking warfarin, a drug with a narrow therapeutic index. Which
laboratory parameter should be monitored to assess therapeutic effect?
A. aPTT
B. INR (International Normalized Ratio)
C. Platelet count
D. Bleeding time
Rationale: Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X). The INR is
the standard monitoring parameter for warfarin therapy, with typical target ranges of 2.0–3.0
for most indications and 2.5–3.5 for mechanical mitral valves .
13. (MCQ) Which statement best describes the concept of volume of distribution (Vd)?
A. The rate at which a drug is eliminated from the body
B. The theoretical volume into which the total drug dose would need to be distributed to
achieve the observed plasma concentration
C. The amount of drug bound to plasma proteins
D. The fraction of drug that reaches systemic circulation
Rationale: Vd = Dose / Plasma concentration. A high Vd indicates extensive tissue
distribution (e.g., digoxin, amiodarone); a low Vd indicates confinement to plasma (e.g.,
warfarin, heparin). Vd influences loading dose calculations .
14. (MCQ) A 55-year-old patient with cirrhosis has decreased albumin levels. The nurse
practitioner should monitor for which potential drug-related complication?
